5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

 

5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology
S

2L Options for EGFR+ NSCLC: How to Treat Osimertinib Resistance? What Is the Role of Anti-Angiogenic Therapy?

By 5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology FEATURING Shayma Kazmi
By 5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology FEATURING Shayma Kazmi
793 views
February 2, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

20:25
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
Lung Cancers
09:53
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

2L Options for EGFR+ NSCLC: How to Treat Osimertinib Resistance? Wha…

Feat. S. Kazmi
15:37
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Update on Early Stage NSCLC: Role of Screening, Neoadjuvant Therapie…

Feat. J. Porter
10:32
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Use of Stereotactic Radiation for NSCLC Pts & Vale of IO after S…

Feat. W. Curran
09:04
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

New RT Approaches to Stage III NSCLC Pts: Can Radiotherapy Be Furthe…

Feat. W. Curran
10:53
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

2020 Update on NSCLC Targeted Therapies: ALK, ROS1, RET, MET, NTRK, …

Feat. S. Kazmi
14:33
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Immunotherapy in NSCLC: Progression, irAE management & Combinati…

Feat. R. Salgia